Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer ModelsOsamu Tohyama, Yasuhiro Funahashi|Journal of Thyroid Research|2014Cited by 479
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathwayYu Kato, Yasuhiro Funahashi|PLoS ONE|2019Cited by 458
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimusMasahiro Matsuki, Yasuhiro Funahashi|Cancer Science|2017Cited by 65
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapyKenji Ichikawa, Yasuhiro Funahashi|Scientific Reports|2020Cited by 59
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitorTakayuki Nakagawa, Yasuhiro Funahashi|Cancer Science|2014Cited by 39